•
China-based Zennova Pharmaceutical Group has reportedly raised close to RMB 100 million (USD 13.9 million) in a Series B financing round, with Hengbao Investment Holdings being the sole participant. The funds raised will be directed towards the commercial manufacturing and market launch of Zennova’s products, as well as new product…
•
Zennova Pharmaceuticals Group, a contract manufacturing organization (CMO) with operations in New Jersey, US, and Chengdu, China, has completed Phase 1 construction on a manufacturing site and R&D center in Chengdu, Sichuan province. The 300,000 square foot facility includes a multi-dosage formulation center, warehousing, and administrative buildings, marking a significant…